United States Endometriosis and Uterine Fibroids Market : Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast

Azoth Analytics has released a research report titled "United States Endometriosis and Uterine Fibroids Market (2024 Edition)" which provides a complete analysis of the United States Endometriosis and Uterine Fibroids industry in terms of market segmentation By Drug Type (GnRH Antagonists, Progesterone, GnRh Agonist and Others), By Route of Administration (Oral, and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The United States Endometriosis and Uterine Fibroids Market showcased growth at a CAGR of 4.09 % during 2020-2023. The market was valued at USD 415.70 Million in 2023 which is expected to reach USD 568.07 Million in 2030. The United States has been experiencing a significant boom in recent years, driven by growing prevalence of the disease due to technological advancements in the diagnostics techniques in the United States, increased awareness towards reproductive disorders, and increased expenditure of capital in the Research and Development organizations in the United States.

Due to the limited number of drugs available for the treatment of Endometriosis and Uterine Fibroids, it becomes imperative to find novel treatment outcomes for enhancing the quality of life of the patients. Surgical removal of the fibroids is the only effective treatment option available for treating the disease. However, many females prefer drug therapies over surgical procedures as they are non-invasive. Endometriosis, on the other hand not only affects the uterus but, it also spreads to other reproductive organs, if not treated properly.

Increased investments by pharmaceutical companies on exploring the efficacy of different classes of hormonal drugs can pave way for a new drug in the market through different routes of administration such as oral, and parenteral. The emergence of newer technologies such as nanocarrier delivery of drugs, skin patches for epidermal drug delivery have increased the preference for drug therapies in the United States.

The landscape of drug development in United States has changed dramatically. Precision medicine has emerged as a result of the elimination of conventional treatment options available for endometriosis and uterine fibroids. Clinicians can prescribe medications based on the clinical presentation, genetic profile, and the severity or stage of endometriosis. Scientists have focused their research on developing tailored medicines for the treatment of endometriosis and uterine fibroids by utilising high resolution omics data and meta-analysis of disease profile.

New avenues in the research and development for endometriosis and uterine fibroids treatment have been made possible by incorporating artificial intelligence and machine learning in drug manufacturing processes. Various distribution channels such as Hospital pharmacies, retail pharmacies or online pharmacies offers widespread delivery of medicine to the consumers especially for those living in remote areas or facing time constraints. In the coming years, the online channels have the potential to elevate the market sales of drugs.

Furthermore, the use of biodegradable implants for delivering hormonal drugs such as progesterone, Gonadotrophin releasing hormone agonists, and Gonadotrophin releasing agonists is one of the trends in the United States endometriosis and uterine fibroid market. These biodegradable implants are biocompatible and non-invasive in nature. In addition to these benefits, drug implants consume less time and can be implemented in the case of controlling the symptoms associated with the diseases.

Scope of the Report:

The report analyses the Global, Americas and United States Endometriosis and Uterine Fibroids Market by Value (USD Million).

The report includes a detailed assessment of United States Endometriosis and Uterine Fibroids Market by Value (USD Million).

The report analyses the United States Endometriosis and Uterine Fibroids Market by Epidemiology.

The report analyses the United States Endometriosis and Uterine Fibroids Market by Pipeline Scenario.

The report presents the analysis of United States Endometriosis and Uterine Fibroids Market for the historical period of 2020-2023, the estimated year 2024, and the forecast period of 2025-2030.

The report analyses the United States Endometriosis and Uterine Fibroids Market, By Drug Type (GnRH Antagonists, Progesterone, GnRh Agonist and Others).

The report analyses the United States Endometriosis and Uterine Fibroids Market By Route of Administration (Oral and Parenteral).

The report analyses the United States Endometriosis and Uterine Fibroids Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies).

The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented By Drug Type, by Route of Administration & by Distribution Channel.

Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.

The report tracks competitive developments, strategies, mergers and acquisitions and new Drug development. The companies analysed in the report include AbbVie Inc., Pfizer Inc., AstraZeneca plc., Tolmar Inc., Glenmark Pharmaceuticals Pvt. Ltd., Aspen Pharmacare Holdings Ltd., Agile Therapeutics Inc., Medicine 360, Cipla Ltd., Takeda Pharmaceuticals.

1. Market Background

1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology

2. Analyst Recommendations

2.1 Augment the availability of combinational drugs
2.2 Escalate Distribution through Online services

3. Global Endometriosis and Uterine Fibroids Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Global Endometriosis and Uterine Fibroids Market
3.2 Global Endometriosis and Uterine Fibroids Market: Dashboard
3.3 Global Endometriosis and Uterine Fibroids Market: Market Value Assessment3.4 Regional Snapshot

4. Americas Endometriosis and Uterine Fibroids Market

4.1 Americas Endometriosis and Uterine Fibroids Market: Market Value Assessment
4.2 Americas Endometriosis and Uterine Fibroids Market: Key Factors
4.3 Americas Endometriosis and Uterine Fibroids Market: Segment Analysis
4.4 Americas Endometriosis and Uterine Fibroids Market: By Country Overview

5. United States Endometriosis and Uterine Fibroids Market

5.1 United States Endometriosis and Uterine Fibroids: Dashboard
5.2 United States Endometriosis and Uterine Fibroids: Market Value Assessment
5.3 United States Endometriosis and Uterine Fibroids: By Drug Type
- 5.3.1 United States Endometriosis and Uterine Fibroids Market, By Drug Type Overview
- 5.3.2 United States Endometriosis and Uterine Fibroids Market Size, By GnRH Antagonists, By Value, 2020H-2030F (USD Million & CAGR)
- 5.3.3 United States Endometriosis and Uterine Fibroids Market Size, By Progesterone, By Value, 2020H-2030F (USD Million & CAGR)
- 5.3.4 United States Endometriosis and Uterine Fibroids Market Size, By GnRH Agonists, By Value, 2020H-2030F (USD Million & CAGR)
- 5.3.5 United States Endometriosis and Uterine Fibroids Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
5.4 United States Endometriosis and Uterine Fibroids: By Route of Administration
- 5.4.1 United States Endometriosis and Uterine Fibroids Market, By Route of Administration Overview
- 5.4.2 United States Endometriosis and Uterine Fibroids Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
- 5.4.3 United States Endometriosis and Uterine Fibroids Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
- 5.3.4 United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4 United States Endometriosis and Uterine Fibroids: By Distribution Channel
- 5.4.1 United States Endometriosis and Uterine Fibroids Market, By Distribution Channel Overview
- 5.4.2 United States Endometriosis and Uterine Fibroids Market Size, By Hospital Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
- 5.4.3 United States Endometriosis and Uterine Fibroids Market Size, By Retail Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
- 5.4.4 United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)

6. United States Endometriosis and Uterine Fibroids Epidemiology and Pipeline Analysis

6.1 Epidemiology: United States Endometriosis and Uterine Fibroids Prevalence
6.2 Epidemiology: United States Endometriosis and Uterine Fibroids Incidence
6.3 Pipeline Scenario

7. Market Dynamics

7.1 Impact Assessment of Market Dynamics on United States Endometriosis and Uterine Fibroids
7.2 Market Dynamics of United States Endometriosis and Uterine Fibroids: Drivers
7.3 Market Dynamics of United States Endometriosis and Uterine Fibroids: Restraints
7.4 Market Dynamics of United States Endometriosis and Uterine Fibroids: Trends

8. Industry Ecosystem Analysis

8.1 Porter Analysis of United States Endometriosis and Uterine Fibroids Market

9. Competitive Positioning

9.1 Companies Product Positioning
9.2 Market Position Matrix
9.3 Market Share Analysis of United States Endometriosis and Uterine Fibroids Market
9.4 Company Profiles
- 9.4.1 AbbVie Inc.
- 9.4.2 Pfizer Inc.
- 9.4.3 AstraZeneca plc.
- 9.4.4 Tolmar Inc.
- 9.4.5 Glenmark Pharmaceuticals Ltd.
- 9.4.6 Aspen Pharmacare Holdings Ltd.
- 9.4.7 Agile Therapeutics Inc
- 9.4.8 Medicines 360
- 9.4.9 Cipla Ltd
- 9.4.10 Takeda Pharmaceuticals

10. About us & Disclaimer

List of Figures

Figure 1: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2020-2023 (USD Million)
Figure 2: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2024-2030 (USD Million)
Figure 3: Americas Endometriosis and Uterine Fibroids Market Size, By Value, 2020H-2030F (USD Million)
Figure 4: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2020-2023 (USD Million)
Figure 5: United States Endometriosis and Uterine Fibroids Market Size, By Value, 2024-2030 (USD Million)
Figure 6: United States Endometriosis and Uterine Fibroids Market Share, By Drug Type, 2023 (%)
Figure 7: Market Attractiveness Analysis of United States Endometriosis and Uterine Fibroid Market, By Drug Type (2025-2030)
Figure 8: United States Endometriosis and Uterine Fibroids Market Size, By GnRH Antagonist, By Value, 2020H-2030F (USD Million & CAGR)
Figure 9: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By GnRH Antagonist, 2020-2030 (USD Million)
Figure 10: United States Endometriosis and Uterine Fibroids Market Size, By Progesterone, By Value, 2020H-2030F (USD Million & CAGR)
Figure 11: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Progesterone, 2020-2030 (USD Million)
Figure 12: United States Endometriosis and Uterine Fibroids Market Size, By GnRH Agonist, By Value, 2020H-2030F (USD Million & CAGR)
Figure 13: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By GnRH Agonist, 2020-2030 (USD Million)
Figure 14: United States Endometriosis and Uterine Fibroids Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
Figure 15: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Others, 2020-2030 (USD Million)
Figure 16: Market Attractiveness Analysis of United States Endometriosis and Uterine Fibroid Market, By Route of Administration (2025-2030)
Figure 17: United States Endometriosis and Uterine Fibroids Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
Figure 18: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Oral, 2020-2030 (USD Million)
Figure 19: United States Endometriosis and Uterine Fibroids Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
Figure 20: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million)
Figure 21: Market Attractiveness Analysis of United States Endometriosis and Uterine Fibroid Market, By Distribution Channel (2025-2030)
Figure 22: United States Endometriosis and Uterine Fibroids Market Size, By Hospital Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
Figure 23: United States Endometriosis and Uterine Fibroids Market Absolute Opportunity, By Hospital Pharmacies, 2020-2030 (USD Million)
Figure 24: United States Endometriosis and Uterine Fibroids Market Size, By Retail Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
Figure 25: United States Elevated Work Platform (Endometriosis and Uterine Fibroids) Market Absolute Opportunity, By Retail Pharmacies, 2020-2030 (USD Million)
Figure 26: United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
Figure 27: United States Elevated Work Platform (Endometriosis and Uterine Fibroids) Market Absolute Opportunity, By Online Pharmacies, 2020-2030 (USD Million)
Figure 28: Global Impact of Drivers and Restraints
Figure 29: Market Share of Prominent Companies of United States Endometriosis and Uterine Fibroids Market, 2023 (%)
Figure 30: AbbVie Inc. Revenue, 2021-2023 (USD Million)
Figure 31: AbbVie Inc. Revenue, By Geographical Segments, 2023 (%)
Figure 32: AbbVie Inc. Revenue, By Business Segments, 2023 (%)
Figure 33: Pfizer Inc. Revenue, 2021-2023 (USD Million)
Figure 34: Pfizer Inc. Revenue, By Geographical Segments, 2023 (%)
Figure 35: Pfizer Inc. Revenue, By Business Segments, 2023 (%)
Figure 36: AstraZeneca plc. Revenue, 2021-2023 (USD Million)
Figure 37: AstraZeneca plc. Revenue, By Geographical Segments, 2023 (%)
Figure 38: AstraZeneca plc. Revenue, By Business Segments, 2023 (%)
Figure 39: Glenmark Revenue, 2021-2023 (USD Million)
Figure 40: Glenmark Revenue, By Geographical Segments, 2023 (%)
Figure 41: Glenmark Revenue, By Business Segments, 2023 (%)
Figure 42: Aspen Pharmaceuticals Revenue, 2021-2023 (USD Million)
Figure 43: Aspen Pharmaceuticals Revenue, By Geographical Segments, 2023 (%)
Figure 44: Aspen Pharmaceuticals Revenue, By Business Segments, 2023 (%)
Figure 45: Agile Therapeutics Inc Revenue, 2021-2023 (USD Million)
Figure 46: Cipla Ltd. Revenue, 2021-2023 (USD Million)
Figure 47: Cipla Ltd. Revenue, By Geographical Segments, 2023 (%)
Figure 48: Cipla Ltd. Revenue, By Business Segments, 2023 (%)
Figure 49: Takeda Revenue, 2021-2023 (USD Million)
Figure 50: Takeda Revenue, By Geographical Segments, 2023 (%)
Figure 51: Takeda Revenue, By Business Segments, 2023 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Endometriosis Drugs in Pipeline

Table A3: Uterine Fibroids Drugs in Pipeline

Table A4: AbbVie Inc. Key Company Financials, 2021-2023

Table A5: Pfizer Inc. Key Company Financials, 2021-2023

Table A6: AstraZeneca plc. Key Company Financials, 2021-2023

Table A7: Glenmark Key Company Financials, 2021-2023

Table A8: Aspen Pharmaceuticals Key Company Financials, 2021-2023

Table A9: Agile Therapeutics Inc. Key Company Financials, 2021-2023

Table A10: Cipla Ltd. Key Company Financials, 2021-2023

Table A11: Takeda Key Company Financials, 2021-2023